Teruo Eguchi

Nihon University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Yasuo Takahashi

Nihon University

Masashi Fujii

Japan Clinical Cancer Research Organization

Shigetomi Iwai

Nihon University

Yukimoto Ishii

Nihon University

Mitsuko Kasahara

Nihon University

Koichi Ishikawa

National Institute of Infectious Diseases

Masashi Fujii

Japan Clinical Cancer Research Organization

Motoo Yamagata

Nihon University

Toshihito Nagata

Nagoya University

Tadatoshi Takayama

Nihon University

Cooperative Institutions

Nihon University

Kitasato University

Surugadai Nihon University Hospital

The University of Tokyo

Nihon University Itabashi Hospital

Kochi Medical School Hospital

Tokyo Gas (Japan)

National Hospital Organization

International University of Health and Welfare

Hiroshima University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Docetaxel plus 5-fluorouracil for terminal gastric cancer patients with peritoneal dissemination.

PubMed (2003)

Teruo Eguchi Masashi Fujii Kazuhiko Wakabayashi Kazuo Aisaki Yutaka Tsuneda

There are few reports on chemotherapy for poor prognosis terminal patients with peritoneal dissemination of gastric cancer, especially in those with renal dysfunction, because of the possibility of severe toxicity. We conducted a study of the combination of docetaxel and 5-fluorouracil for the treatment of these patients to improve quality of life because of its low toxicity.Five patients were treated in this study. All patients had a large volume of carcinomatous fluid in the abdomen, without liver or distant metastasis. The respective doses of docetaxel and 5-fluorouracil were 60 mg/m2 on day 1 and 370 mg/m2 on days 1 to 5 by intravenous infusion. Patients received this treatment 2-7 times every 2-3 weeks.Grade III/IV toxicity occurred, consisting of neutropenia (100%) and diarrhea (40%). No patients developed renal dysfunction. Carcinomatous fluid volume diminished for 15-96 days. Quality of life questionnaire score and performance status scale was significantly improved from 75-86 to 51-61 (p = 0.041) and 3-4 to 0-1 (p = 0.039), respectively. All patients were able to leave hospital after this treatment. Four of five patients died and median survival time was 223 days. Two of five patients achieved partial response and three patients showed no response (response rate 40%).This new combination therapy had benefit for terminal patients with peritoneal dissemination of gastric cancer.

Performance status

Source

Cite

Citations (8)

A RESECTED CASE OF PRIMARY CANCER OF THE APPENDIX PRESENTING WITH A HUGE METASTATIC LESION IN THE OVARY

The journal of the Japanese Practical Surgeon Society (1997)

Teruo Eguchi Motoo Yamagata Toshiyuki Yamagata Hisashi Furuhata Kazuhide Otsuka

Primary cancer of the appendix is a rare entity. We experienced a patient with the disease who was seen at the hospital because of a lower abdominal tumor and was operated on with a diagnosis of ovarian cancer, but intraoperative frozen section diagnosis resulted in that the ovarian lesion was a metastasis from a cancer of the appendix. This paper describes this rare case with a review of the literature. A 46-year-old woman was admitted to the gynecological & obstetrical department in our hospital because of a lower abdominal tumor. There were an adult's head sized tumor in the lower abdomen, pleural effusion and ascites. Ultrasonography and CT revealed aninternally heterogenous tumor with irregular margin in the ovary. Laparotomy was performed with a diagnosis of ovarian tumor. The tumor existed in the left ovary, and a swelling of the ileocecal lymph nodes and claval hypertrophy of the appendix were noted. In addition intraoperative frozen section diagnosis was ovarian metastasis of signet ring cell carcinoma. The patient was definitely diagnosed as cancer of the appendix with an ovarian metastasis. Excision of the ileocecal region, simple hysterectomy, and bilateral adnexectomy were carried out. The excised specimen revealed mixed-type and moderately differentiated adenocarcinoma arising in the appendix with metastases to the left ovary as well as the uterus and right ovary.

Ovarian tumor

Metastatic carcinoma

10.3919/ringe1963.58.878

Cite

Citations (2)

Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer.

PubMed (2000)

Mitsuko Kasahara Yasuo Takahashi Toshihito Nagata Satoshi Asai Teruo Eguchi

Thymidylate synthase (TS) is thought to be one of the target genes that the E2F1 transcription factor binds to and regulates. However, the relationship between the expressions of TS and E2F1 in primary colon cancer specimens remains unclear. The aim of this study was to define the relation of TS and E2F1 gene expressions in tumor samples from 23 colon cancer patients. TS and E2F1 gene expressions were measured by TaqMan reverse transcription-PCR assay using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal standard and expressed as a TS:GAPDH or E2F1:GAPDH mRNA ratio. A close relationship was found between TS gene expression and E2F1 gene expression (r2 = 0.598, P < 0.001) in 23 tumor samples analyzed. Surprisingly, a high correlation between TS gene expression and E2F1 gene expression was observed even in advanced tumors from stage IV colon cancer patients. These results suggest that transcription of the TS gene may be regulated by E2F1 in primary colon cancer specimens and that this gene-regulatory pathway from E2F1 to TS may be highly conserved during malignant progression. Four of the 23 patients showed TS overexpression with increased E2F1 expression. These results suggest that the ability of a tumor to increase TS expression may possibly be due to an overexpression of E2F1. Although the number of patients was relatively small, our study provides new insights into the molecular mechanisms underlying the regulation of TS expression in colon cancers.

E2F1

Glyceraldehyde 3-phosphate dehydrogenase

Transcription

Source

Cite

Citations (66)

Detection of Aberrations of 17p and p53 Gene in Gastrointestinal Cancers by Dual (Two-color) Fluorescence In Situ Hybridization and GeneChip p53 Assay

Cancer Genetics and Cytogenetics (2000)

Yasuo Takahashi Toshihito Nagata Satoshi Asai Kaori Shintaku Teruo Eguchi

10.1016/s0165-4608(00)00231-4

Cite

Citations (14)

Study of long intestinal tube for decompression of obstructive left colon cancer.

PubMed (1999)

Teruo Eguchi Yasuo Takahashi Shuji Asai Yoshiyuki Ishii Masakazu Fujii

Recently, several reports have recommended primary resection, rather than a staged operation, for obstructive left colon cancer. However pre-operative decompression is important for reducing complications and improving the curability of primary resection. Among the many pre-operative decompression strategies reported, we selected the long intestinal tube and evaluated the effectiveness of this convenient strategy.A long intestinal tube was inserted pre-operatively for decompression in 27 of 29 patients undergoing resection for obstructive left colon cancer (1991-1995). We retrospectively studied the clinical features (responders vs. non-responders) of the 27 patients. We also compared these 27 with 26 other pre-1990 patients, who did not receive pre-operative decompression, in term of post-operative morbidity.Twelve of the 27 patients were responders; success rate 44.4%. There were no blood profile differences between responders and non-responders, but the time from bowel movement cessation to intestinal tube insertion was 3 days or less in all responders but 4 days or more in non-responders (p<0.001). There was no significant difference in the rate of post-operative morbidity between those with and without pre-operative decompression.Decompression is likely to be successful, allowing elective primary resection, when initiated within 3 days of bowel movement cessation. However, more than 4 days post-onset, other decompression methods or emergency surgery is necessary.

Source

Cite

Citations (2)

The Studies of Clinicopathological Features and Treatments of Obstructive Colorectal Cancer.

The Japanese Journal of Gastroenterological Surgery (1996)

Teruo Eguchi Toshisada Ueda Masahiko Nakamura Toyozou Kitajima Shigetomi Iwai

大腸癌イレウスの臨床病理学的特徴とその治療, 特に緊急手術の適応について検討した. 1976年から1994年までの大腸癌手術症例は252例で, そのうちイレウス症状を呈した症例 (イレウス群) は31例 (12. 3%) であった. イレウス群は非イレウス群に比べ男性に多く, 肉眼的には3型, 全周性が, 組織学的には深達度ss以上, n (+), ly (+), v (+) が多かった. 肝転移, 腹膜転移も多く, stage IIIa以上の進行癌が多かった. イレウス群のなかで1期的に切除しえた症例は分割手術が施行された症例よりも治癒切除率は高かった. 当院ではチューブドレナージによる待期的な1期的吻合治癒切除をすすめているが, 左側結腸では症例により緊急手術としている. その基準として,(1) イレウス発症から治療開始までに1週間が経過している,(2) 局所に強い圧痛を持っている,(3) 4日間のチューブドレナージで効果の現れないものとした.

10.5833/jjgs.29.2116

Cite

Citations (5)

[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].

PubMed (1992)

Hiroko Taguchi Ichiro Kubonishi N Takehara Y Uemura Y Iwahara

Intensive induction chemotherapy was applied to 25 patients with acute myelogenous leukemia by continuing drugs (daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone) until the achievement of severe bone marrow aplasia (leukemic cells less than 1,000/microliters). Complete remission (CR) was achieved in 18 (72%). Numbers of partial remission and an early death were 5 (20%) and 2 (8%), respectively. Although median nadirs of white blood cells (WBC) and platelet counts (Pl) (205/microliters and 8,200/microliters, respectively) were remarkably low, recovery of WBC (over 1,000/microliters) and Pl (over 50,000/microliters) were achieved in 23.8 and 24.5 days, after an initiation of the chemotherapy. Sepsis was a most frequently observed complication during induction stage and a duration of fever was 2-48 days (median 15). Median duration of CR was 22.9 months. Unexpectedly, 11 of 17 CR (except one with bone marrow transplanted) relapsed after 4.2-41.4 months (median; 9.4), but 6 (35.3%) still remain in first CR for 30.5-72.9 months (median; 51.4). A long-term survival might be obtained by intensifying induction chemotherapy in about one fourth of patients, but the intensification or application of non-cross resistant anti-leukemic agents in post-remission therapy may be required to avoid relapses even if induction is intensified.

Daunorubicin

Prednisolone

Mercaptopurine

Aplasia

Induction chemotherapy

Bone marrow suppression

Source

Cite

Citations (0)

Gastric Cancer in Young Patients

Journal of the American College of Surgeons (1999)

Teruo Eguchi Yasuo Takahashi Motoo Yamagata Mitsuko Kasahara Masashi Fujii

10.1016/s1072-7515(98)00268-3

Cite

Citations (57)

Pheochromocytoma Presenting as an Abdominal Emergency: Association with Perforation of the Colon

Digestion (2002)

Takero Mazaki Junko Hara Yoshihiro Watanabe Shigeru Suzuki Tomohisa Kohno

A pheochromocytoma is a rare tumor derived from the adrenal medulla (or from chromaffin cells of sympathetic ganglia). Its symptoms derive mostly from the excessive release of catecholamines (adrenaline and noradrenaline). Hypertension is the most recognized feature of this disease, but gastrointestinal manifestations can on rare occasions be just as serious and life threatening. This report describes a rare case of a 70-year-old woman with pheochromocytoma who developed an acute abdominal emergency with shock and panperitonitis as a result of perforation of the descending colon which was effectively treated by surgical removal of the tumor and the perforated colon. There have been 2 such cases in the English literature in whom a pheochromocytoma was associated with perforation of the colon. Successful surgical removal of such a pheochromocytoma has been not reported previously. Our case demonstrates the importance of recognizing that a pheochromocytoma presents with a wide spectrum of manifestations, and rapid treatment brings improvement to the patient.

Perforation

10.1159/000051933

Cite

Citations (8)

Mortality for gastric cancer in elderly patients

Journal of Surgical Oncology (2003)

Teruo Eguchi Masashi Fujii Tadatoshi Takayama

The aim of this study was to clarify the surgical outcome in elderly patients with gastric cancer.The clinicopathological features of elderly patients (80 (3.7%), over 80 years, elderly group) were reviewed retrospectively and compared with those of younger patients (2095 (96.3%), 23-79 years, control group).The elderly group had a significantly higher prevalence of concomitant disease (P < 0.0001), while the prevalence of T1 primary tumor, N0 lymph node metastasis, and stage I was lower (P = 0.0125, P = 0.0004, P < 0.0001). The rates of resected cases and curative operation (R0) were significantly lower in the elderly group (P < 0.0001, P = 0.0021). The mortality from other diseases was 16.3% in elderly patients and 4.4% in control patients (P < 0.0001). The 5-year survival of stage I and stage IV were not significantly different between the two groups (P = 0.1266 and P = 0.2490). The overall survival and disease-specific survival for all patients in the elderly group were significantly lower than those in the control group (P < 0.0001, P = 0.0102). However, disease-specific survival for resected cases was not significantly different between the two groups (P = 0.0725).In elderly patients, the reason for the poor prognosis is the high rate of advanced stage and the high rate of death from other diseases.

Concomitant

10.1002/jso.10303

Cite

Citations (75)